Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 21 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/1/1998


1.		Phase III Prospective, Open-Label, Parallel-Group, Randomized, Multicenter Trial Comparing the Efficacy of Surgery, Radiation, and Injection of Murine Cells Producing Herpes Simplex Thymidine Kinase Vector Followed by Intravenous Ganciclovir Against the Efficacy of Surgery and Radiation in the Treatment of Newly Diagnosed, Previously Untreated Glioblastoma Multiforme (Summary Last Modified 06/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GTI-0115 NCI-V96-0990

Last Modified: 4/11/2007 First Published: 5/1/2001


2.		Phase III Randomized Study of Valganciclovir to Prevent Late Cytomegalovirus Infection in Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				16 and over				NCI				FHCRC-1577.00 MSKCC-01127, NCI-H01-0072, NCT00016068

Last Modified: 6/1/1997


3.		Phase I/II Study of Stereotactic Injection of the Herpes Simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir for Recurrent Malignant Glioma (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 18				Other				UCMC-95-3-20-2 NCI-V95-0681

Last Modified: 8/1/1996


4.		Phase I/II Study of In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir for Recurrent Glioblastoma Multiforme (Summary Last Modified 08/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				UCMC-95-3-20-1 NCI-V95-0682

Last Modified: 2/1/1998


5.		Phase I/II Study of Intratumoral Gene Therapy: Stereotactic Injection of the Herpes Simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir in Progressive or Recurrent Primary Supratentorial Pediatric Malignant Brain Tumors (Summary Last Modified 02/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				3 to 21				Pharmaceutical / Industry				GTI-0106 NCI-V96-0989

Last Modified: 8/1/1993


6.		Phase I/II Gene Therapy Study of Intratumoral Transduction with the Herpes simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir in Adults with Recurrent Brain Tumors (Summary Last Modified 08/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NINDS				NINDS-92-N-0246

Last Modified: 3/20/2003 First Published: 4/1/2000


7.		Phase II Study of In Vivo Gene Therapy With Herpes Simplex Thymidine Kinase in Women With Refractory or Relapsed Ovarian Epithelial Adenocarcinoma, Fallopian Tube Cancer, or Peritoneal Cancer (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				HGTRI-0105 NCI-V00-1584, NCT00005025

Last Modified: 1/8/2007 First Published: 9/1/2000


8.		Phase II Study of Zidovudine, Interleukin-2, and Ganciclovir in Patients With Primary AIDS Related Central Nervous System Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				AMC-019 NCT00006264, AMC-019

Last Modified: 7/10/2007 First Published: 9/16/2005


9.		Phase II Pilot Study of Targeted Oncolytic Virotherapy Comprising Bortezomib, Zidovudine, and Valganciclovir Followed By Effusion Drainage and Bevacizumab in Combination With Chemotherapy Comprising Cyclophosphamide, Doxorubicin, and Etoposide in Patients With Primary Effusion Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-05-C-0203 NCI-P6330, NCT00217503

First Published: 9/11/2007


10.		Phase II Pilot Study of Intravenous Ganciclovir Followed By Oral Ganciclovir in Patients With Reactivated Cytomegalovirus After Allogeneic Bone Marrow Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Supportive care, Treatment				Closed				18 and over				NCI				CHNMC-98074 98074, NCT00530218

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute